Amylx Pharmaceuticals Inc vs Gogoro Inc — how do they compare? Amylx Pharmaceuticals Inc trades at $23.66 (market cap $2.64B), while Gogoro Inc trades at $2.63 (market cap $52.19M). The key difference: Amylx Pharmaceuticals Inc is far larger — about 50.6× Gogoro Inc's market cap, and Amylx Pharmaceuticals Inc is trading nearer its 52-week high, Gogoro Inc nearer its low. Which is the better fit depends on your goals.
| AMLX | GGR | |
|---|---|---|
Market Cap | $2.64B | $52.19M |
Sector | Health | Technology |
52-Week High | $24.19 | $7.50 |
52-Week Low | $7.82 | $2.55 |
Enterprise Value | $2.39B | $354.63M |
Signals from Pluang's Aura AI — not financial advice
AMLX trades at $23.61, up 4.15% today, with strong analyst support (91% buy ratings) and a $30 consensus price target. The stock shows bullish technical momentum despite negative profitability metrics (ROE -74.73%, ROA -66.25%). Recent Q2 2026 earnings missed expectations, but the company maintains $250.8M cash runway into 2028, supporting its pivotal Phase 3 LUCIDITY trial readout expected August-September 2026.
The investment thesis hinges on successful avexitide clinical outcomes, with potential 2027 launch offering significant upside. Key risks include ongoing financial losses, clinical trial execution, and competitive pressures. Current valuation at 11.02x book value appears stretched given negative earnings, making positive trial results critical for justifying premium pricing.
No Aura AI signal available yet.
Trailing returns across standard periods
Amylyx Pharmaceuticals is a biopharmaceutical firm focused on developing therapies for rare diseases. Its pipeline includes treatments for conditions like post-bariatric hypoglycemia and congenital hyperinsulinism.
Read more on AMLX →Gogoro is a global technology leader in battery-swapping ecosystems for electric two-wheelers. It provides smart, sustainable urban mobility solutions and manages an extensive network of battery stations.
Read more on GGR →